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Perivascular Epithelioid Cell Tumor of Gastrointestinal Tract
Case Report and Review of the Literature
Biyan Lu, MD, PhD, Chenliang Wang, MD, Junxiao Zhang, MD, Roland P. Kuiper, PhD,
Minmin Song, MD, Xiaoli Zhang, MD, Shunxin Song, MD, Ad Geurts van Kessel, PhD,
Aikichi Iwamoto, MD, PhD, Jianping Wang, MD, PhD, and Huanliang Liu, MD, PhD
Perivascular epithelioid cell tumors of gastrointestinal tract (GI PECo-
mas) are exceedingly rare, with only a limited number of published
reports worldwide. Given the scarcity of GI PEComas and their
relatively short follow-up periods, our current knowledge of their
biologic behavior, molecular genetic alterations, diagnostic criteria,
and prognostic factors continues to be very limited.
We present 2 cases of GI PEComas, one of which showed an
aggressive histologic behavior that underwent multiple combined che-
motherapies. We also review the available English-language medical
literature on GI PEComas-not otherwise specified (PEComas-NOS) and
discuss their clinicopathological and molecular genetic features.
Pathologic analyses including histomorphologic, immunohisto-
chemical, and ultrastructural studies were performed to evaluate the
clinicopathological features of GI PEComas, their diagnosis, and differ-
ential diagnosis. Immunohistochemistry, semiquantitative reverse tran-
scriptase polymerase chain reaction, and DNA sequencing assays were
carried out to detect the potential molecular genetic alterations in our
cases
Microscopically, the tumors showed distinctive histologic features
of PEComas-NOS, including fascicular or nested architecture, epithe-
lioid or spindled cell type, and clear to eosinophilic cytoplasm. The
tumor cells were immunohistochemically positive for melanocytic
markers. Molecular pathological assays confirmed a PSF-TFE3 gene
fusion in one of our cases. Furthermore, in this case microphthalmia-
associated transcription factor and its downstream genes were found to
exhibit elevated transcript levels.
Knowledge about the molecular genetic alterations in GI PEComas
is still limited and warrants further study.
(Medicine 94(3):e393)
Abbreviations: AML = angiomyolipoma, CCMMT = clear cell
myomelanocytic tumor of the falciform ligament/ligamentum teres,
CCST = clear cell ‘‘sugar’’ tumor of the lung, CDK2 = cyclin-
dependent kinase 2, C-MET = met proto-oncogene, CRP = C-
reactive protein, CT = computed tomography, DCT = dopachrome
tautomerase, GAPDH = glyceraldehyde-phosphate dehydrogenase,
G-CSF = granulocyte colony-stimulating factor, GI PEComas =
perivascular epithelioid cell tumors of gastrointestinal tract, HIF-1a
= hypoxia inducible factor 1, alpha subunit. HMB45 = human
melanoma black 45, HPF = high power field, LAM = lym-
phangioleiomyomatosis, MiTF = microphthalmia-associated
transcription factor, NBI = narrow-band imaging, PEComas =
perivascular epithelioid cell tumors, PEComas-NOS = PEComas-
not otherwise specified, PECs = perivascular epithelioid cells, PR =
pathogenesis related protein, pSTAT3 = phospho-signal transducers
and activators of transcription 3, Q3W = once every 3 weeks, RT-
PCR = semiquantitative reverse transcriptase polymerase chain
reaction, SMA = smooth muscle actin, TBX2 = T-box 2, TFE3 =
Transcription factor E3, TSC = tuberous sclerosis complex, TYR =
tyrosinase, WBC = white blood cell.
INTRODUCTION
P erivascular epithelioid cell tumors (PEComas) are a familyof rare mesenchymal neoplasms histologically and immu-
nohistochemically characterized by perivascular epithelioid cell
(PEC) differentiation.1 The PECs have variable morphologic
features, with an epithelioid to spindled cell type resembling
smooth muscle, clear to granular lightly eosinophilic cytoplasm,
and round to oval nuclei with small nucleoli. The PECs also
exhibit a distinct immunophenotype with a coexpression of
melanocytic and myogenic markers, such as HMB45, Melan-A,
MiTF, smooth muscle actin (SMA), and calponin.2 The
PEComa family includes angiomyolipoma (AML), clear cell
‘‘sugar’’ tumor of the lung (CCST), lymphangioleiomyomato-
sis (LAM), clear cell myomelanocytic tumor of the falciform
ligament/ligamentum teres (CCMMT), and unusual clear cell
tumors in other locations. PEComas have been reported in
various anatomic sites, with a marked female predominance.
Due to their relative rarity, the diagnostic criteria, optimal
treatment strategies, and prognostic factors for PEComas have
not yet been confirmed at this time. We report 2 cases of
PEComas arising in the gastrointestinal tract, including the
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clinicopathological features and potential molecular genetic
alterations of this rare tumor.
MATERIALS AND METHODS
Case Presentation
Case 1
A 29-year-old Chinese woman was admitted to our hospi-
tal because of gradual onset of abdominal pain, nausea, vomit-
ing and weight loss for 6 months.3 The patient did not have a
medical history of gastrointestinal tumors, inflammatory bowel
disease, or tuberous sclerosis complex. Her family history was
unremarkable. Physical examination revealed a large mass at
the right lower abdomen. All blood and biochemical tests were
within the normal ranges, apart from a hemoglobin reading of
85 mg/dL and a C-reactive protein (CRP) reading of 15 mg/dL.
An intravenous contrast-enhanced computed tomography (CT)
scan showed an ill-defined multilocular soft tissue tumor
measuring 13 cm 8 cm 7 cm in the pelvis and lower
abdomen (Figure 1). During the surgical operation, a large
tumor was found in the terminal ileum about 12 cm from
ileocecal valve adhering tightly to the mesentery of the ileum
and the right pelvic wall. Surgical resection of the tumor and the
affected segment of the intestine was carried out. After surgery,
the patient received 5 courses of multiple combined che-
motherapies including ifosfamide 2000 mg/m2 day 1 to 4,
epidoxorubicin 30 mg/m2 day 1 to 3, dacarbazine 350 mg/m2
day 1 to 4, and mesna 4800 mg/m2 day 1 to 4 once every 3 weeks
(Q3W). In addition, granulocyte colony-stimulating factor (G-
CSF; Filgrastim) was given at a dose of 5 pg/kg/day subcu-
taneously from day 5 to day 12 of each cycle. Follow-up CT
scans were performed every 6 months after chemotherapy. The
patient was alive and well with no signs of recurrence or
metastasis for 28 months of follow-up.
Case 2
A 41-year-old Chinese woman with a history of hyster-
ectomy for benign leiomyoma presented with progressive epi-
gastric pain and dark stools. The patient denied any family
A B
C D
FIGURE 1. Abdominal computed tomography images (case 1): coronal (A), sagittal (B), and axial (C and D) reconstructions. Computed
tomography of the abdomen showed an ill-defined multilocular low-density mass measuring 1387cm in the pelvis and lower
abdomen.
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history of gastrointestinal (GI) cancer or inflammatory bowel
disease. Laboratory investigations showed a white blood cell
(WBC) count of 11.6 109 cells/L with 87.3% neutrophils and
a hemoglobin reading of 100 mg/dL. Serum levels of CA19-9,
CEA, AFP, and CA125 were within normal limits. The abdomi-
nal CT scan and ultrasonography revealed ileocecal intussus-
ception with a tumor in the ileum. An enteroscopy displayed a
2-cm diameter, polypoid, submucosal tumor in the terminal
ileum (Figure 2). At laparotomy, neither celiac lymphadenec-
tasis nor distant metastatic foci were detected. Approximately,
45 cm of the terminal ileum (20 cm) and proximal colon (25 cm)
were resected. Without additional therapy, the patient remained
asymptomatic and free of disease at 39 months postoperatively.
Histologic and Immunohistochemical Analyses
The tumor tissues were fixed in 10% phosphate buffered
saline formalin solution and embedded in paraffin. Tissue
sections were stained with hematoxylin and eosin for micro-
scopic examination. Immunohistochemical stainings were per-
formed with the primary antibodies listed in Table 1 by using the
DAKO Envision detection kit (Dako Cytomation, Carpinteria,
CA), according to standard procedures. The Ki-67 labeling
index was defined as the percentage of MIB-1-positive cells
among at least 500 tumor cells in 5 representative fields. This
study was approved by the Committee of the Institute of
Research and Medical Ethics at Sun Yat-Sen University.
Electron Microscopy
The tumor samples were collected and fixed in 4% phos-
phate-buffered solution of glutaraldehyde and osmium
A B
FIGURE 2. Endoscopy appearance of GI PEComa (case 2). White light (A) and narrow band imaging (B) endoscopy showed a 2-cm
diameter, polypoid tumor protruding into the lumen of the terminal ileum. GI PEComa¼perivascular epithelioid cell tumors of
gastrointestinal tract.
TABLE 1. Immunohistochemical Results of the 2 Cases
Antibody Source Dilution Case 1 Case 2
HMB45 Abcam 1:50 þ þ
Melan-A DAKO 1:30  þ
TFE3 Abcam 1:50 þ 
Desmin Abcam 1:150  þ
Vimentin Abcam 1:500  
SMA Abcam 1:400  þ
HHF35 Abcam 1:100  þ
S-100 protein Abcam 1:350  
Synaptophysin Abcam 1:1000  
Chromogranin A Abcam 1:400  
AE1/AE3 Abcam 1:50  
CD34 Abcam 1:50  
CD117 Santa Cruz 1:200  
CD10 Santa Cruz 1:100  
AMACR Abcam 1:50  
WT-1 Abcam 1:100  
ER Abcam 1:100  
PR Abcam 1:100  þ
Cyclin D1 Abcam 1:100  
pSTAT3 Abcam 1:200 þ 
P53 Abcam 1:100  
Ki-67 Abcam 1:200 5% < 1%
Abcam, Abcam Ltd, Cambridge, United Kingdom; Dako, Dako
Cytomation, Carpinteria, USA; Santa Cruz, Santa Cruz Biochemistry,
CA, USA FIGURE 3. Resected specimens of perivascular epithelioid cell
tumor arising in the terminal ileum (case 1).
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A B
C D
E F
G H
HMB45 pSTAT3
TEF3 CyclinD1
FIGURE 4. Microscopic features of the ileum tumor (case 1). The tumor consisted of an epithelioid cell proliferation with a vaguely nested
pattern (A). In some areas, the tumor displayed a pseudoglandular histological appearance (B). The perivascular epithelioid cells had clear
to eosinophilic granular cytoplasm with some slightly irregular nucleus nuclei (C). Foci of coagulation necrosis were also found in the
tumor (D). The tumor cells were positive for HMB45 (E), pSTAT3 (F), and TFE3 (G), and negative for Cyclin D1 (H).
Lu et al Medicine  Volume 94, Number 3, January 2015
4 | www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
tetroxide. Ultrathin sections were cut for ultrastructural evalu-
ation using a Tecnai G2 Spirit TWIN electron microscope (FEI
Co, Eindhoven, Netherlands).
Reverse Transcription-Polymerase Chain
Reaction and Sequencing
A reverse transcription-polymerase chain reaction (RT-
PCR) assay was performed to detect related gene fusions. Total
RNA was isolated from the tumor tissues using TRIzol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. The first strand of cDNA was obtained using
RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas,
Vilnius, Lithuania). PCR was performed with rTaq polymerase
(Takara Shuzo, Ohtsu, Japan). The PCR primers and cycling
conditions were performed as described in Table 2. The result-
ing PCR products were analyzed in 1.5% agarose electrophor-
etic gels using DL1, 000 DNA Marker (Takara Shuzo) as a size
FIGURE 5. Cross-section of perivascular epithelioid cell tumor
arising in the terminal ileum (case 2).
A B
C D
E F
HMB45 SMA
CD34 PR
FIGURE 6. Microscopic features of the ileum tumor (case 2). The tumor showed clear spindle-shaped cells arranged in fascicular and
nesting patterns (A and B). The tumor cells expressed HMB45 (C), SMA (D), and PR (F). SMA¼ smooth muscle actin, PR¼pathogenesis-
related protein
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reference. Gel images were obtained with Gene Genius (Syn-
gene, Frederick, MD). The specific PCR product was sent to
Shanghai Invitrogen Biotechnology Co., Ltd (Guangzhou
Office) for purification and sequencing. In the analysis of MiTF
and its downstream genes expression, malignant melanoma
tissue served as a positive control, and normal intestinal mucosa
distant from cancer served as a negative control.
RESULTS
Pathologic Findings
Case 1
On gross examination, an ill-defined tumor measuring
13.5 7.5 7.0 cm was found at the terminal ileum about
12 cm from ileocecal valve (Figure 3). The cut surface showed
a pinkish-grey solid parenchyma, with several scattered and
irregular cystic spaces containing clear colorless serous fluid.
The tumor mainly involved the muscularis propria, and pro-
truded into the tunica adventitia, while the mucosa and sub-
mucosa were still intact. The right pelvic side wall and
mesentery of the ileum were invaded by the tumor. Regional
lymph nodes and lymphovascular invasions were void of any
tumor. Microscopically, the tumor showed epithelioid cell
proliferation with a vaguely nested pattern (Figure 4A). The
nests were separated by thin fibrovascular septa. Some areas
showed a pseudoglandular histological appearance (Figure 4B).
The tumor cells had clear to eosinophilic granular cytoplasm.
Some slightly irregular nuclei with scattered prominent nucleoli
were focally present (Figure 4C). Foci of tissue necrosis and
occasional mitoses (35/50HPF) were found in the tumor
FIGURE 7. Transmission electron microscopy showing melano-
somes and premelanosomes (case 1).
TABLE 2. Details of Primers Used in the Study
Primer Name Primer Sequence (5’!3’) Tm (8C)
GAPDH (F) AGAAGGCTGGGGCTCATTTG 57.5
GAPDH (R) AGGGGCCATCCACAGTCTTC
PSF (F) TGGTGGTGGCATAGGTTATG 59
TFE3 (R) CGTTTGATGTTGGGCAGCTC
NonO (F) GAGAAACTAGACACAGCAAC 59
TFE3 (R) CTTTCTTCTGCCGTTCCTTC
PRCC (F) CCAAGCCAAAGAAGAGGA 59
TFE3 (R) AGTGTGGTGGACAGGTACTG
EWS (F) CCCACTAGTTACCCACCCCA 60
ATF-1 (R) AAAACTCCACTAGGAAATCCATTT
Cyclin D1 (F) AACTACCTGGACCGCTTCCT 60
Cyclin D1 (R) CCACTTGAGCTTGTTCACCA
TBX2 (F) AGTGGATGGCTAAGCCTGTG 58
TBX2 (R) ACGGGTTGTTGTCGATCTTC
TYR (F) TACGGCGTAATCCTGGAAAC 62
TYR (R) ATTGTGCATGCTGCTTTGAG
MiTF-M (F) AGGGAGCTCACAGCGTGTAT 57
MiTF-M (R) GAGCCTGCATTTCAAGTTCC
DCT (F) GGTTCCTTTCTTCCCTCCAG 63
DCT (R) AACCAAAGCCACCAGTGTTC
C-MET (F) CAGGCAGTGCAGCATGTAGT 60
C-MET (R) GATGATTCCCTCGGTCAGAA
CDK2(F) CATTCCTCTTCCCCTCATCA 60
CDK2(R) CAGGGACTCCAAAAGCTCTG
HIF-1a(F) GAAAGCGCAAGTCCTCAAAG 62
HIF-1a(R) TGGGTAGGAGATGGAGATGC
CDK2¼ cyclin-dependent kinase 2, C-MET¼met proto-oncogene, DCT¼ dopachrome tautomeras, F¼ forward, GAPDH¼ glyceraldehyde-
phosphate dehydrogenase, HIF-1a¼ hypoxia inducible factor 1, alpha subunit, MiTF¼microphthalmia-associated transcription factor, R¼ reverse,
TM¼ temperature at which 50% of given oligonucleotide are hybridized to its complementary stard, TYR¼ tyrosinase.
Lu et al Medicine  Volume 94, Number 3, January 2015
6 | www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Marker
Lane 1: GAPDH (case 1)
Case 1 Case 2
PSF exon 9
PSF PQ P RBD
PQ P RBD
ADD bHLH Z TFE3
GAPDH CyclinD1 HIF-1α C-MET DTC TYR MiTF TBX2
Positive control
Case 2
Negative control
Case 1
bHLH Z
TFE3 exon 6
Breakpoint
400bp
700bp
300bp
200bp
100bp
Lane 2: SPF-TFE3 (case 1)
Lane 3: Non0-TFE3 (case 1)
Lane 5: EWS-ATF-1 (case 1)
Lane 4: PRCC-TFE3 (case 1)
Lane 6: GAPDH (case 2)
Lane 7: SPF-TFE3 (case 2)
Lane 8: Non0-TFE3 (case 2)
Lane 10: EWS-ATF-1 (case 2)
Lane 9: PRCC-TFE3 (case 2)
1 2 3 4 5 6 7 8 9 10
A
B
C
D
FIGURE 8. Molecular pathological analyses for PEComas. Detection of the related gene fusion fragments was performed by RT-PCR. A
distinct band of 186bp in length (lane 2) was amplified in case 1 (A). DNA sequencing demonstrated that the transcript was composed of
fusions of exon 9 of thePSF gene to exon 6 of the TFE3 gene (B andC). Semiquantitative RT-PCRwas performed to analyze the expression
levels of MiTF, TYR, C-MET, DTC, TBX2, CDK2, and Cyclin D1.MiTF, TYR, CDK2, TBX2, and C-METwere up-regulated in the tumor sample
of case 1 (D). PEComa¼perivascular epithelioid cell tumors; RT-PCR¼ reverse transcription-polymerase chain reaction.
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(Figure 4D). Immunohistochemically, the tumor cells were
positive for HMB45, TFE3, and pSTAT3 (Figure 4E-4G),
whereas all other markers tested were negative (Table 1).
Case 2
Grossly, a 2.2-cm diameter, polypoid, submucosal tumor
was located in the terminal ileum protruding into the lumen. On
cut section, the tumor was well-circumscribed but not encap-
sulated (Figure 5). Histologic examination revealed clear spin-
dle-shaped cells arranged in fascicular and nesting patterns,
separated by thin fibrovascular septa (Figure 6A-B). The nuclei
were mainly round and vesicular. Neither mitosis nor necrosis
was identified in the tumor. Immunohistochemical analysis
revealed that the tumor cells expressed HMB45, Melan-A,
SMA, HHF35, Desmin, and pathogenesis-related protein
(Figure 6C–F), and were negative for all other markers tested
(Table 1).
The above pathologic findings in our cases confirmed a
final diagnosis of GI PEComas-NOS.
Electron Microscopy
Melanosomes and premelanosomes were identified in the
cytoplasm of both cases, using electron microscopy (Figure 7).
Molecular Pathological Studies
An RT-PCR assay was performed to detect related gene
fusions, including PSF-TFE3, NonO-TFE3, PRCC-TFE3, and
EWS-ATF-1.4 A distinct band of 186 bp in length (lane 2) was
amplified in case 1, representing the PSF-TFE3 fusion fragment
(Figure 8A). Sequencing of the amplified DNA revealed that the
PSF-TFE3 fusion transcript contained an in-frame junction of
exon 9 of the PSF gene to exon 6 of the TFE3 gene (Figure 8B
and C). Analyses regarding the expression levels of MiTF and
its downstream genes showed that MiTF, TYR, CDK2, TBX2,
and C-MET were upregulated in the tumor sample of case 1
(Figure 8D). Case 2 was also tested here,, but no fusion genes
were found.
Literature Review
English-language medical reports on GI PEComas-NOS
were searched for on PubMed and Embase using the search
terms PEComa and gastrointestinal tract or bowel. Their clin-
icopathological features were reviewed and tabulated in
Table 3.1,5–30
DISCUSSION
According to theWorld Health Organization Classification
of tumors, PEComas are defined as a family of rare mesench-
ymal neoplasms histologically and immunohistochemically
characterized by PEC differentiation.31 The PEComa family
includes AML, CCST, LAM, CCMMT, and unusual clear cell
tumors in other locations.32–35 The latter subgroup, which has
been collectively classified as PEComas-NOS, represents a
collection of unusual, histologically and immunohistochemi-
cally distinctive tumors arising at various anatomic sites such as
the uterus, gastrointestinal tract, and soft tissue.31,35 The GI tract
is the second most common site of PEComas-NOS, accounting
for 20% to 25% of all PEComas-NOS cases. To the best of our
knowledge, only 70 cases (including the current reports) of GI
PEComas-NOS have currently been reported in the English
language medical literature (Table 3). The most common
location of GI PEComas-NOS was the colon (n¼ 32),5–14,36
followed by the small intestine (n¼ 20),1,15–18,36,37 rectum
(n¼ 7),19–24 and stomach (n¼ 4).25,26,36 Of the patients, 43
were females and 27 were males, with a ratio of 2:1. The age at
diagnosis ranged from 5.5 to 71 years. Until now, all reported
cases of GI PEComas-NOS were sporadic, and only 1 patient
was associated with tuberous sclerosis syndrome. Given the
rarity of GI PEComas-NOS and their relatively short follow-up
periods, our current knowledge of their biologic behavior,
natural history, criteria for malignancy, and prognostic factors
is limited.
From recent clinical data, it appears that GI PEComas-
NOS exhibit a spectrum of biologic behavior from benign to
malignant. The majority of reported GI PEComas-NOS were
considered to be benign or to have uncertain malignant poten-
tial, whereas only 22 cases (22/70) exhibited definite malignant
behavior, with local recurrence in 4 cases, metastasis in 19
cases, and tumor-related death in 7 cases.1,9,10,12,15,17,21,26,29,36
The proposed histologic features indicative of malignancy or
high risk for aggressive clinical behavior in GI PEComas-NOS
by Folpe et al38 include infiltrative growth pattern, tumor size
(>5 cm), high nuclear grade, tumor necrosis, high mitotic
activity (>1/50 HPF), and lymphovascular invasion. A recent
case series study of 35 GI PEComas has shown that malignant
behavior was statistically significantly associated with marked
nuclear atypia, diffuse pleomorphism, and mitoses 2/10 HPF,
but not with tumor necrosis.36 Optimal treatment strategies for
GI PEComas-NOS have not yet been well established. Cur-
rently, surgical resection with a wide margin seems to be the
mainstay of treatment. The benefit of adjuvant chemotherapy,21
radiation, and immunotherapy8 has not yet been established. In
case 1, the tumor showed features of malignancy in the form of
large size (13.5 7.5 7.0 cm), surrounding tissue invasion,
necrosis, and high mitotic activity (35/50 HPF). Given the
high risk of tumor aggressive behavior, the patient was treated
with multiple combined chemotherapies after surgery on the
basis of nonrhabdomyosarcoma soft tissue sarcoma protocol
(COG-ARST0332). She was alive and well with no signs of
recurrence or metastasis for 28 months of follow-up. However,
the benefit of adjuvant chemotherapy is still an area of con-
troversy that requires more evidence-based studies.
Knowledge about the molecular genetic alterations in
PEComas is still limited. Some cases of AML, CCST, LAM,
and CCMMT have been reported to be associated with tuberous
sclerosis complex (TSC), a genetic disease caused by hetero-
zygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) genes,
whereas only one of the reported cases of GI PEComas-NOS
showed an association with TSC until now. However, Cyclin
D1 overexpression has been detected by immunohistochemistry
in 5 cases of PEComas-NOS that were either malignant or had
an uncertain malignant potential.12,21,39 The role of Cyclin D1
in the pathogenesis and progression of PEComas is becoming an
area of interest. However, no Cyclin D1 immunoreactivity was
evident in the 2 current cases. In recent years, it has been
reported that a distinctive subset of PEComas harbors TFE3
gene fusion.40 Tanaka et al11 reported the first case of GI
PEComa-NOS with a PSF-TFE3 gene fusion. In this study,
we have confirmed the PSF-TFE3 gene fusion in another GI
PEComa-NOS (case 1). In addition, MiTF and its downstream
genes including TYR, CDK2, TBX2, and C-METwere detected
in elevated transcript levels. TFE3 and MiTF belong to the
MiTF/TFE transcription factor family, which is believed to be
involved in pivotal developmental and cellular processes in
various cell types. In different human tissues, the ratio of
expression of the MiTF/TFE family members is found to be
Lu et al Medicine  Volume 94, Number 3, January 2015
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unique.41 Translocations of these genes are implicated in the
MiT translocation subgroup of renal cell carcinomas.42,43
Recently, TFE3 has also been found to be an efficient regulator
in melanocyte differentiation and pigment production under
specific pathological conditions in vitro.44 Also, results from
several recent clinical studies support the hypothesis that TFE3
can substitute for MiTF in a subset of MiTF-negative PECo-
mas.10,13,38 As previously proposed by others,10,13,40,45,46 the
subset of tumors harboring TFE3 gene fusions or exhibiting
TFE3 immunoreactivity share distinctive clinicopathological
features including relatively young age, nested/alveolar archi-
tecture, epithelioid cells with eosinophilic cytoplasm, and
negative immunoreactivity for MiTF or muscular markers.
Some studies also confirmed that overexpression of the
TFE3 fusion protein is necessary for proliferation, migration,
invasion potential, and long-term survival of UOK-145 cell
lines.47,48 These findings suggest that TFE3 may play an
important role in the tumorigenesis, and warrants further study.
In summary, we report 2 cases of PEComas-NOS arising in
the GI tract, one of which was confirmed to harbor a PSF-TFE3
gene fusion and to exhibit upregulation of MiTF and its down-
stream genes. Although the contribution of TFE3 to the patho-
genesis and progression of PEComas-NOS remains poorly
understood, the assessment of the TFE3 gene status may be
necessary for an accurate diagnosis and prognosis of PEComas-
NOS.
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